Ignite Creation Date:
2025-12-25 @ 1:37 AM
Ignite Modification Date:
2026-02-20 @ 4:09 PM
Study NCT ID:
NCT04874194
Status:
TERMINATED
Last Update Posted:
2025-11-03
First Post:
2021-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hematopoietic and Lymphoid Cell Neoplasm | View |
| None | Recurrent Acute Biphenotypic Leukemia | View |
| None | Recurrent Acute Myeloid Leukemia | View |
| None | Recurrent Myelodysplastic Syndrome | View |
| None | Refractory Acute Biphenotypic Leukemia | View |
| None | Refractory Acute Myeloid Leukemia | View |
| None | Refractory Myelodysplastic Syndrome | View |
Keywords: